An 11.6-point drop on a 56-point anxiety scale, 5.4 points better than placebo, from a single dosing session lasting about six and a half hours. The second positive Phase 3 for the drug this year.
4,500 cases and 2,060 deaths in Ituri, spreading faster than any previous outbreak. WHO is proposing to randomise contacts individually rather than by ring — a change with real trade-offs.
Retatrutide is not approved anywhere and will not be filed until 2027. It is already being sold online as a weight-loss hack — and Lilly has flagged 14,000 websites across 100 countries.
The scientist who showed CAR-T could drive lupus into remission has co-founded a company trying to achieve the same reset without cells — with $65 million and three approaches.
The lateral septum sits between knowing a reward exists and feeling compelled to pursue it. It is dense with GLP-1 receptors — which may explain why these drugs quiet cravings beyond food.
Deaths were 7.2% in the stop group and 7.9% in the continue group over three years. LDL rose 50%. Both facts are the result, and reconciling them is the point.
Clinicians avoid steroids in infection because suppressing inflammation is assumed to suppress defence. In infected human macrophages, dexamethasone separated the two.
One lot of an intravenous arthritis biosimilar, recalled to user level after an internal investigation found glass particles in the vials.
K2 does not discover drugs. It licenses them, mostly from China, and its new CEO ran the company behind one of the first China-to-US commercial successes.
Four RAS(ON) inhibitors paired with a PRMT5 inhibitor and a trispecific antibody. BeOne funds and runs a global Phase 3; Revolution keeps everything outside select Asian markets.
12.1% weight loss from a chemically manufactured tablet. The molecule being small rather than a peptide is what would change who can get these drugs.
Innate keeps developing the drug; Sobi takes commercialisation on accelerated approval. A structure that lets a research-stage company reach patients without building a sales force.